Mediation of nonerosive arthritis in a mouse model of lupus by interferon-α-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis

Arthritis and Rheumatism

Volumn 62, Issue 4, 2010, Pages 1127-1137

  Mensah, Kofi A ^a   Mathian, Alexis ^b   Ma, Lin ^c   Xing, Lianping ^c   Ritchlin, Christopher T ^c   Schwarz, Edward M ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD11B ANTIGEN; GLYCOPROTEIN P 15095; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTHRITIS; ARTICLE; BLOOD; BONE EROSION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL STIMULATION; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HISTOLOGY; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACTINS; ANIMALS; BONE AND BONES; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; OSTEOCLASTS; OSTEOGENESIS; RNA; SPLEEN;

EID: 77950528208     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27312     Document Type: Article

References (38)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361
2. Kaarela K, Luukkainen R, Koskimies S. How often is seropositive rheumatoid arthritis an erosive disease? A 17-year followup study. J Rheumatol 1993;20:1670-1673 (Pubitemid 24017567)
3. Kaarela K, Sarna S. Correlations between clinical facets of outcome in rheumatoid arthritis. Clin Exp Rheumatol 1993;11:643-644 (Pubitemid 24000164)
4. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309 (Pubitemid 129516268)
5. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis [review]. Arthritis Rheum 2000;43:2143-2151
6. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-831 (Pubitemid 37074957)
7. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, et al. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-792 (Pubitemid 34214261)
8. Kaposi M. New reports on knowledge of systemic lupus erythematosus. Arch Dermatol Syph 1872;4:36-78. In German.
9. Stevens M. Musculoskeletal manifestations. In: Shur PH, editor. The clinical management of systemic lupus erythematosus. New York: Grune & Stratton; 1983. p. 63-84.
10. Esdaile JM, Danoff D, Rosenthall L, Gutkowski A. Deforming arthritis in systemic lupus erythematosus. Ann Rheum Dis 1981;40:124-126
11. Grigor R, Edmonds J, Lewkonia R, Bresnihan B, Hughes GR. Systemic lupus erythematosus: a prospective analysis. Ann Rheum Dis 1978;37:121-128
12. Molina JF, Citera G, Rosler D, Cuellar ML, Molina J, Felipe O, et al. Coexistence of human immunodeficiency virus infection and systemic lupus erythematosus. J Rheumatol 1995;22:347-350
13. Pascual V, Banchereau J, Palucka AK. The central role of dendritic cells and interferon-α in SLE. Curr Opin Rheumatol 2003;15:548-556 (Pubitemid 37041391)
14. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004;20:539-550 (Pubitemid 38638124)
15. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8.
16. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982;216:429-431
17. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401-406
18. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-723 (Pubitemid 36350866)
19. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-2615 (Pubitemid 36297546)
20. Cunnane G, Lane NE. Steroid-induced osteoporosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:311-29,vi-vii.
21. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197:777-788 (Pubitemid 36350872)
22. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005;174:2499-2506 (Pubitemid 40279662)
23. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 2002;416:744-749 (Pubitemid 34429151)
24. Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G, et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001;15:435-443 (Pubitemid 32907390)
25. Schwarz EM, Looney RJ, Drissi MH, O'Keefe RJ, Boyce BF, Xing L, et al. Autoimmunity and bone. Ann N Y Acad Sci 2006;1068:275-283
26. Buie HR, Moore CP, Boyd SK. Postpubertal architectural developmental patterns differ between the L3 vertebra and proximal tibia in three inbred strains of mice. J Bone Miner Res 2008;23:2048-2059
27. Proulx ST, Kwok E, You Z, Papuga MO, Beck CA, Shealy DJ, et al. Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum 2007;56:4024-4037 (Pubitemid 350262330)
28. Flick LM, Weaver JM, Ulrich-Vinther M, Abuzzahab F, Zhang X, Dougall WC, et al. Effects of receptor activator of NFκB (RANK) signaling blockade on fracture healing. J Orthop Res 2003;21:676-684 (Pubitemid 36758211)
29. Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 2002;3:360-365
30. Ji H, Gauguier D, Ohmura K, Gonzalez A, Duchatelle V, Danoy P, et al. Genetic influences on the end-stage effector phase of arthritis. J Exp Med 2001;194:321-330 (Pubitemid 32730806)
31. Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, Takagi K, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001;98:2544-2554
32. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000;191:1777-1788 (Pubitemid 30331574)
33. Adachi Y, Taketani S, Toki J, Ikebukuro K, Sugiura K, Oyaizu H, et al. Marked increase in number of dendritic cells in autoimmuneprone (NZW x BXSB)F1 mice with age. Stem Cells 2002;20:61-72. (Pubitemid 34118911)
34. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-1916 (Pubitemid 43877940)
35. Lian ZX, Kikuchi K, Yang GX, Ansari AA, Ikehara S, Gershwin ME. Expansion of bone marrow IFN-α-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-α in NZB bone marrow. J Immunol 2004;173:5283-5289 (Pubitemid 39387812)
36. Ishida Y, Heersche JN. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res 1998;13:1822-1826 (Pubitemid 28535838)
37. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006;116:2152-2160 (Pubitemid 44162324)
38. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008;58:3485-3497